1. Inici
  2. Publicacions
  3. CLINICAL NOTE: Marchiafava-Bignami disease in a patient with schizophrenia and alcohol use disorder

CLINICAL NOTE: Marchiafava-Bignami disease in a patient with schizophrenia and alcohol use disorder

Data de publicació: Data Ahead of Print:

Autors de IIS La Fe

Grups d'Investigació

Abstract

Introduction. Substance-related disorders are the most frequent comorbidity in schizophrenia. Concretely, alcohol is the most commonly consumed substance after tobacco. Patients with schizophrenia with this comorbidity have a worse clinical course and can develop serious neuropsychiatric complications. One of them, Marchiafava-Bignami disease (MBD) can be incorrectly diagnosed as a decompensation of their mental disorder. Methods. A case of a 51-year-old man, diagnosed with schizophrenia and alcohol use disorder is presented. He experienced acute neuropsychiatric symptoms for which schizophrenia decompensation was suspected. Based on his atypical symptoms and medical history, a brain imaging test was performed and MBD was diagnosed. Conclusions. MBD is an infrequent clinical entity that should be part of differential diagnosis in patients with alcohol abuse disorder experiencing atypical neuropsychiatric symptoms.

Dades de la publicació

ISSN/ISSNe:
1139-9287, 1578-2735

ACTAS ESPANOLAS DE PSIQUIATRIA  JUAN JOSE LOPEZ-IBOR FOUNDATION

Tipus:
Letter
Pàgines:
228-231
DOI:
PubMed:
34533206
Factor d'Impacte:
0,372 SCImago ℠
Quartil:
Q3 SCImago ℠

Cites Rebudes en Web of Science: 1

Documents

  • No hi ha documents

Mètriques

Filiacions mostrar / ocultar

Keywords

  • Marchiafava-Bignami disease; schizophrenia; dual disorder; alcohol use disorders

Projectes associats

EFECTOS DE LA MONOTERAPIA CON LITIO EN EL FUNCIONAMIENTO NEUROPSICOLOGICO DE LOS PACIENTES CON TRASTORNO BIPOLAR

Investigador Principal: LORENZO LIVIANOS ALDANA

SM I 22/2011 . 2012

CARACTERIZACIÓN EPIGENÓMICA DE LA ANOREXIA NERVIOSA. MODELO DE GEMELAS MONOCIGOTAS DISCORDANTES Y VALIDACIÓN EN POBLACIÓN GENERAL.

Investigador Principal: LUIS MIGUEL ROJO MORENO

PI16/01279 . INSTITUTO DE SALUD CARLOS III . 2017

COMPRENSIÓN DEL LENGUAJE FIGURATIVO Y ANÁFORAS EN LECTORES CON TRASTORNOS DEL ESPECTRO AUTISTA DESARROLLO: ESTUDIO DE MOVIMIENTOS OCULARES Y POTENCIALES EVOCADOS.

Investigador Principal: INMACULADA FAJARDO BRAVO

AICO/2016 . 2016

ESTUDIO ALEATORIZADO, DOBLE CIEGO DE LA EFICACIA Y SEGURIDAD DE REBOXETINA COMPARADO CON VELAFAXINA EN PACIENTES CON DEPRESION MAYOR GRAVE.

Investigador Principal: LUIS MIGUEL ROJO MORENO

M/2020/0026

Compartir la publicació